功能获得性RHOA突变促进弥漫性胃癌中黏着斑激酶激活及依赖
该研究探讨弥漫性胃癌中高频RHOA错义突变的功能,发现RHOAY42C为功能获得性致癌突变,与Cdh1失活共同诱导小鼠转移性弥漫性胃癌,并激活FAK及下游YAP-TAZ、PI3K-AKT和β-catenin信号;RHOAY42C小鼠模型对FAK抑制及YAP联合PI3K阻断敏感,患者来源细胞系亦对FAK抑制敏感,提示FAK为潜在治疗靶点。
要点
- RHOAY42C是弥漫性胃癌中最常见的RHOA突变,为功能获得性致癌突变。
- RHOAY42C与Cdh1失活协同诱导小鼠转移性弥漫性胃癌。
- RHOAY42C模型对FAK抑制及YAP联合PI3K阻断敏感。
核心结论
- RHOAY42C是功能获得性致癌突变,与Cdh1失活共同诱导转移性弥漫性胃癌。
- RHOA突变通过激活FAK及下游YAP-TAZ、PI3K-AKT和β-catenin信号促进肿瘤发生。
- FAK抑制在RHOAY42C小鼠模型和患者来源弥漫性胃癌细胞系中显示敏感性,提示FAK为潜在靶点。
研究设计与样本
- 采用生化研究和小鼠模型研究RHOA热点突变Y42C的功能。
- 使用患者来源的弥漫性胃癌细胞系评估FAK抑制的敏感性。
主要发现
- RHOAY42C表现出GTP水解受损并增强与效应蛋白ROCK的相互作用。
- RHOA Y42C突变和Cdh1缺失诱导肌动蛋白/细胞骨架重排及黏着斑激酶(FAK)活性。
- FAK激活下游YAP-TAZ、PI3K-AKT和β-catenin信号。
- RHOAY42C小鼠模型对FAK抑制和YAP联合PI3K通路阻断敏感。
- 患者来源弥漫性胃癌细胞系对FAK抑制敏感。
关键数值与推荐
- RHOAY42C是弥漫性胃癌中最常见的RHOA突变。
临床怎么用
- 对于携带RHOA Y42C突变且Cdh1失活的弥漫性胃癌,可考虑FAK抑制或YAP联合PI3K通路阻断策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diffuse gastric cancer (DGC) is a lethal malignancy lacking effective systemic therapy. Among the most provocative recent results in DGC has been that of highly recurrent missense mutations in the GTPase RHOA. The function of these mutations has remained unresolved. We demonstrate that RHOAY42C, the most common RHOA mutation in DGC, is a gain-of-function oncogenic mutant, and that expression of RHOAY42C with inactivation of the canonical tumor suppressor Cdh1 induces metastatic DGC in a mouse model. Biochemically, RHOAY42C exhibits impaired GTP hydrolysis and enhances interaction with its effector ROCK. RHOA Y42C mutation and Cdh1 loss induce actin/cytoskeletal rearrangements and activity of focal adhesion kinase (FAK), which activates YAP-TAZ, PI3K-AKT, and β-catenin. RHOAY42C murine models were sensitive to FAK inhibition and to combined YAP and PI3K pathway blockade. These results, coupled with sensitivity to FAK inhibition in patient-derived DGC cell lines, nominate FAK as a novel target for these cancers. SIGNIFICANCE: The functional significance of recurrent RHOA mutations in DGC has remained unresolved. Through biochemical studies and mouse modeling of the hotspot RHOAY42C mutation, we establish that these mutations are activating, detail their effects upon cell signaling, and define how RHOA-mediated FAK activation imparts sensitivity to pharmacologic FAK inhibitors.See related commentary by Benton and Chernoff, p. 182.This article is highlighted in the In This Issue feature, p. 161.
引用
- Zhang H, Schaefer A, Wang Y, et al. Gain-of-Function RHOA Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric Cancer. Cancer Discov. 2019. PMID: 31771969. doi:10.1158/2159-8290.CD-19-0811
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。